Friday, November 29, 2013 8:35:34 AM
Between October 8, 2013 and October 30, 2103 we sold an aggregate of 4,587,940 units of our securities to accredited investors in a private placement exempt from registration under the Securities Act, in reliance on exemptions provided by Section 4(a)(2) and Rule 506(b) of Regulation D. The units were sold at a purchase price of $0.50 per unit resulting in gross proceeds to us of $2,293,970. We also issued 212,206 units to our placement agent as payment of $106,030 of fees and expenses. Each unit consisted of one share of our Class A common stock and one three year Class A Common Stock Purchase Warrant to purchase 0.5 shares of our Class A common stock, resulting the issuance of 4,800,000 shares of our Class A common stock and Class A Common Stock Purchase Warrants to purchase an additional 2,400,000 shares of our Class A common stock. T.R. Winston & Company, LLC, a broker-dealer and member of FINRA, acted as placement agent for us in this offering. In addition to the 212,206 units referenced above, we paid the placement agent and a selling agent commissions and a non-accountable expense allowance totaling $181,976 and issued it three year warrants to purchase 480,000 of our Class A common stock at an exercise price of $1.00 per share.
Expect MASSIVE DILUTION.
Recent SRAX News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/03/2024 08:05:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2024 08:05:41 PM
- SRAX SELECTS XDEFI AS WEB3 WALLET PARTNER, ENABLING SECURE ACCESS TO DIGITAL ASSETS FOR ACTIVE EQUITY INVESTORS • GlobeNewswire Inc. • 03/05/2024 01:30:00 PM
- SRAX SHAREHOLDER LETTER • GlobeNewswire Inc. • 12/18/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/08/2023 08:43:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/28/2023 08:05:45 PM
- SRAX Creates Advisory Board With Company’s Largest Shareholders • GlobeNewswire Inc. • 07/17/2023 08:30:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM